| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-042 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于拟对外投资设立产业基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 拟投资基金名称：广州增城区南特生物医药投资合伙企业（有限合伙） （暂定名，最终以市场监督管理机关登记的名称为准；以下简称"产业基金""基 金"或"合伙企业"）。 ● 拟投资方向：主要投资于早、中期生物医药类项目，包括但不限于：精 准诊断试剂及 IVD、基因检测、细胞治疗、高端医疗器械国产化替代及材料研发、 智慧医疗与信息化、医疗大健康服务等领域，可与公司主营业务生命科学制品在 研发、应用等方面形成协同效应。 ● 拟投资金额：基金规模为人民币 5,001 万元，公司作为有限合伙人拟以 自有资金或自筹资金认缴出资人民币 2,500 万元，占总出资比例 49.99%。 ● 投资基金存续期限：合伙企业作为基金的存续期限为 7 年，自全体 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-041 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届董事会第二十一次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十一 次会议于 2025 年 7 月 3 日以现场及通讯相结合方式召开，会议通知已于 2025 年 7 月 2 日通过通讯方式送达全体董事，经全体董事一致同意豁免提前 5 日通知。 本次会议由董事长袁建华先生召集并主持，应参加董事 7 人，实际参加表决董 事 7 人。本次会议的召集、召开和表决程序均符合国家有关法律、法规及《公 司章程》等有关规定。经全体董事一致同意，形成决议如下： 特此公告。 具体内容详见同日刊载于上海证券交易所网站（www.sse.com.cn）的《关于 拟对外投资设立产业基金的公告》。 二、以 7 票同意，0 票反对，0 票弃权，审议通过了《关 ...

Core Viewpoint - Jiet Bio plans to establish an industrial fund to invest in early and mid-stage biopharmaceutical projects, with a total fund size of 50.01 million yuan [1] Investment Details - The fund will be initiated in partnership with Guangzhou Nanyue Aoyang Fund Management Co., Ltd. and Guangzhou Nanyue Fund Group Co., Ltd. [1] - Jiet Bio intends to contribute 25 million yuan, representing a 49.99% stake in the fund [1] - The partnership will have a duration of 7 years, with the first 4 years designated for investment and the last 3 years for exit [1] Transaction Nature - The investment does not constitute a related party transaction or a major asset restructuring [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本季度转股情况：公司向不特定对象发行可转换公司债券证券"洁特转 债"自 2023 年 1 月 4 日起可转换为公司股份。自 2025 年 4 月 1 日至 2025 年 6 月 30 日期间，"洁特转债"共有人民币 0 元已转换为公司股票，转股数量为 0 股，占"洁特转债"转股前公司已发行股份总额的 0%。 | 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-039 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 可转债转股结果暨股份变动公告 ● 累计转股情况：截至 2025 年 6 月 30 日，"洁特转债"累计有人民币 3,000 元已转换为公司股票，转股数量为 60 股，占"洁特转债"转股前公司已发行股 份总额的 0.00004%。 ● 未转股可转债情况：截至 2025 年 6 月 30 日，"洁特转债"尚未转股的 可转债金额为人民币 439,997,000 元 ...

Core Points - Jiet Bio (688026) closed at 15.86 yuan on June 27, 2025, up 5.17% from the previous week's 15.08 yuan [1] - The company's total market capitalization is 2.226 billion yuan, ranking 116th out of 126 in the medical device sector and 4825th out of 5151 in the A-share market [1] Company Announcements - Jiet Bio announced the interest payment for "Jiet Convertible Bonds" for the year 2025, with a face value of 100 yuan per bond and an interest amount of 1.00 yuan (including tax) [1] - The bond interest record date is June 27, 2025, with the ex-dividend date and payment date set for June 30, 2025 [1] - The company issued 4.4 million convertible bonds in June 2022, raising a total of 440 million yuan, with a six-year term and an increasing interest rate, reaching 1.00% in the third year [1] - The interest payment for this period covers from June 28, 2024, to June 27, 2025, with a net interest distribution of 0.80 yuan after a 20% personal income tax [1]

Core Viewpoint - The credit rating agency has assigned a stable outlook to Guangzhou Jiete Biological Filtration Co., Ltd., reflecting its solid operational foundation and stable cooperation with global life science industry leaders, despite facing certain risks related to capacity digestion and reliance on overseas clients [3][6][16]. Company Overview - Guangzhou Jiete Biological Filtration Co., Ltd. specializes in the research, production, and sales of cell culture and related liquid handling life science consumables, maintaining a strong R&D capability in the field [3][5]. - The company has a credit rating of A+ with a stable outlook, indicating a good financial position and manageable debt levels [3][6]. Financial Performance - As of March 2025, the company's total assets reached 17.05 billion, with equity attributable to shareholders at 12.06 billion and total debt at 3.70 billion [3][4]. - The company's revenue for 2024 was 5.59 billion, with a net profit of 0.73 billion, showing a recovery in both revenue and profit scales [3][4]. - The cash-to-short-term debt ratio was notably high at 104.08, indicating strong liquidity [4][5]. Market Position - The company holds a significant position in the domestic supply chain for biological laboratory consumables, with stable cooperation with high-quality clients [6][9]. - The global life science industry giants continue to be major clients, ensuring a steady revenue stream [6][16]. Industry Environment - The life science industry in China has seen rapid growth in research funding, increasing from 59.7 billion in 2017 to 141.5 billion in 2023, with a compound annual growth rate of 15.5% [9][10]. - The market for biological laboratory consumables is projected to grow from 16.49 billion in 2022 to 23.42 billion in 2024, with a compound annual growth rate of 19.17% [10][11]. Risks and Challenges - The company faces uncertainties in capacity digestion and is highly dependent on overseas clients, with 66.13% of its revenue coming from international sales [5][16]. - The reliance on imported raw materials poses risks related to price fluctuations and geopolitical factors, which could adversely affect the company's performance [5][16]. Future Outlook - The credit rating agency maintains a stable outlook for the company, citing its strong cash position and low debt levels as positive indicators for future performance [6][9]. - The company is expected to continue benefiting from its established relationships with global life science leaders, although it must navigate the challenges posed by market competition and external economic factors [6][16].

Group 1 - The company's credit rating remains at A+ with a stable outlook for both the company and its convertible bonds [1][2] - The credit rating agency Zhongzheng Pengyuan conducted a follow-up credit rating for the company on June 26, 2025, confirming the ratings [2] - The previous credit rating was also A+ with a stable outlook, assessed on June 26, 2024 [1][2] Group 2 - The follow-up rating report was published on the Shanghai Stock Exchange website on the same day as the rating [2]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-038 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于"洁特转债"跟踪信用评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 前次债券评级：公司主体信用等级为 A+，评级展望为"稳定"，"洁特 转债"的信用等级为 A+。 本次债券评级：公司主体信用等级为 A+，评级展望为"稳定"，"洁特 转债"的信用等级为 A+。 广州洁特生物过滤股份有限公司董事会 2025 年 6 月 28 日 2 根据《上市公司证券发行注册管理办法》《上海证券交易所科创板股票上市 规则》等有关规定，广州洁特生物过滤股份有限公司（以下简称"公司"）委托 信用评级机构中证鹏元资信评估股份有限公司（以下简称"中证鹏元"）对公司 于 2022 年 6 月向不特定对象发行的可转换公司债券（以下简称"洁特转债"） 进行了跟踪信用评级。 公司前次主体信用评级结果为 A+， ...

广州洁特生物过滤股份有限公司 相关债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【397】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经 ...

Core Viewpoint - The company, Guangzhou Jiete Biological Filtration Co., Ltd., is implementing a differentiated dividend distribution plan for the year 2024, which is based on the number of shares available after accounting for shares repurchased and held in a special account [1][2][5]. Group 1: Reasons for Differentiated Dividend - The differentiated dividend is a result of the company's decision to repurchase shares using its own or raised funds, with a total repurchase amount between RMB 20 million and RMB 40 million, and a maximum repurchase price of RMB 19.36 per share [1][2]. - The repurchased shares will not participate in profit distribution, leading to the need for a differentiated dividend distribution plan [2][3]. Group 2: Dividend Distribution Plan - The company plans to distribute a cash dividend of RMB 0.73 per 10 shares (including tax) to all shareholders based on the total share capital minus the repurchased shares [2][3]. - The actual number of shares participating in the distribution is 137,632,306 shares, calculated from the total share capital of 140,363,220 shares after deducting the repurchased shares [3][4]. Group 3: Calculation Basis for Differentiated Dividend - The cash dividend per share is calculated based on the adjusted total share capital, and the reference price for ex-dividend trading is determined using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [3][4]. - The impact of the differentiated dividend on the ex-dividend reference price is minimal, with an absolute value change of less than 1% [4]. Group 4: Verification Opinion - The sponsoring institution, Minsheng Securities, confirms that the differentiated dividend distribution complies with relevant laws and regulations, ensuring no harm to the interests of the company and all shareholders [5][6].